Exscientia (NASDAQ:EXAI) Stock Price Down 5%

Exscientia plc (NASDAQ:EXAI - Get Free Report)'s share price dropped 5% on Friday . The stock traded as low as $4.14 and last traded at $4.14. Approximately 172,243 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 711,775 shares. The stock had previously closed at $4.36.

Wall Street Analyst Weigh In

Separately, Bank of America lowered shares of Exscientia from a "buy" rating to a "neutral" rating and decreased their target price for the company from $11.00 to $9.00 in a report on Friday, January 5th.

Exscientia Stock Down 2.8 %

The company has a market capitalization of $512.57 million, a P/E ratio of -2.86 and a beta of 0.78. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.22 and a current ratio of 6.22. The firm's fifty day moving average is $5.82 and its 200-day moving average is $5.84.

Exscientia (NASDAQ:EXAI - Get Free Report) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. The company had revenue of $3.10 million for the quarter, compared to analyst estimates of $41.63 million. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. As a group, equities research analysts predict that Exscientia plc will post -1.76 EPS for the current year.

Institutional Investors Weigh In On Exscientia

Several hedge funds and other institutional investors have recently made changes to their positions in EXAI. DekaBank Deutsche Girozentrale acquired a new stake in Exscientia during the 3rd quarter worth approximately $344,000. Banque Pictet & Cie SA acquired a new stake in Exscientia during the 3rd quarter worth approximately $1,040,000. China Universal Asset Management Co. Ltd. boosted its position in Exscientia by 359.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company's stock worth $34,000 after buying an additional 4,104 shares during the period. Platinum Investment Management Ltd. boosted its position in Exscientia by 10.2% during the 3rd quarter. Platinum Investment Management Ltd. now owns 4,395,058 shares of the company's stock worth $19,866,000 after buying an additional 405,426 shares during the period. Finally, Federated Hermes Inc. acquired a new stake in Exscientia during the 3rd quarter worth approximately $362,000. 41.58% of the stock is owned by institutional investors.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.